Table 1. Characteristics of the study... | American Society of Hematology

Table 1.

Characteristics of the study cohort

Variable	n or median	% or range
Sex
Female	204	43.3
Male	267	56.7
Age, y	68	60-85
ECOG performance status
0	205	43.5
1	200	42.5
2	52	11
3	9	1.9
NA	5	1.1
HCT comorbidity index
0	354	75.2
1	108	22.9
NA	9	1.9
Type of AML
De novo	390	82.8
Post–MDS	68	14.4
Treatment related	13	2.8
WBC, ×10⁹/L	5.3	0.3-546.6
Cytogenetic risk*
Good	13	2.8
Intermediate	339	72
Poor	84	17.8
NA	35	7.4
ELN2017
Favorable	133	28.2
Intermediate	129	27.4
Adverse	195	41.4
NA	14	3
Follow-up, months (IQR)	44.8	43.0-49.9
CR/CRp
After 1 course	311	66
After 2 courses	30	6.4
No	130	27.6

Variable	n or median	% or range
Sex
Female	204	43.3
Male	267	56.7
Age, y	68	60-85
ECOG performance status
0	205	43.5
1	200	42.5
2	52	11
3	9	1.9
NA	5	1.1
HCT comorbidity index
0	354	75.2
1	108	22.9
NA	9	1.9
Type of AML
De novo	390	82.8
Post–MDS	68	14.4
Treatment related	13	2.8
WBC, ×10⁹/L	5.3	0.3-546.6
Cytogenetic risk*
Good	13	2.8
Intermediate	339	72
Poor	84	17.8
NA	35	7.4
ELN2017
Favorable	133	28.2
Intermediate	129	27.4
Adverse	195	41.4
NA	14	3
Follow-up, months (IQR)	44.8	43.0-49.9
CR/CRp
After 1 course	311	66
After 2 courses	30	6.4
No	130	27.6

IQR, interquartile range; MDS, myelodysplastic syndrome; NA, not available.

Defined in supplemental Table 1, with details in supplemental Table 4.